Comparison of artesunate–mefloquine and artemether–lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial

[1]  Koichi Kameda.  Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil. , 2014, Developing world bioethics.

[2]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[3]  A. Dash,et al.  Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India. , 2013, Journal of vector borne diseases.

[4]  K. Oshikoya,et al.  Comparative safety of artemether-lumefantrine and other artemisinin-based combinations in children: a systematic review , 2013, Malaria Journal.

[5]  S. Wells,et al.  The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case study , 2013, Malaria Journal.

[6]  P. Marchesini,et al.  Effect of artesunate-mefloquine fixed-dose combination in malaria transmission in amazon basin communities , 2012, Malaria Journal.

[7]  P. Siba,et al.  Population Pharmacokinetics of Artemether, Lumefantrine, and Their Respective Metabolites in Papua New Guinean Children with Uncomplicated Malaria , 2011, Antimicrobial Agents and Chemotherapy.

[8]  I. Hastings.  How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. , 2011, Trends in parasitology.

[9]  Elizabeth Ashley,et al.  Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial , 2010, The Lancet. Infectious diseases.

[10]  L. Dubowitz,et al.  The neurological assessment in young children treated with artesunate monotherapy or artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria , 2009, Malaria Journal.

[11]  A. Dicko,et al.  A randomized trial of artesunate-mefloquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. , 2008, The American journal of tropical medicine and hygiene.

[12]  M. Meremikwu,et al.  Efficacy, safety and tolerability of artesunate-mefloquine in the treatment of uncomplicated Plasmodium falciparum malaria in four geographic zones of Nigeria , 2008, Malaria Journal.

[13]  K. Mendis,et al.  A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. , 2007, The American journal of tropical medicine and hygiene.

[14]  Oumar Faye,et al.  Efficacy and tolerability of four antimalarial combinations in the treatment of uncomplicated Plasmodium falciparum malaria in Senegal , 2007, Malaria Journal.

[15]  F. Nosten,et al.  An open label randomized comparison of mefloquine–artesunate as separate tablets vs. a new co‐formulated combination for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand , 2006, Tropical medicine & international health : TM & IH.

[16]  K. M. Bhatt,et al.  Efficacy and safety of an artesunate/mefloquine combination, (artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya. , 2006, East African medical journal.

[17]  A. Sowunmi,et al.  Neuropsychiatric side effects of mefloquine in Africans. , 1993, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[18]  N. White,et al.  Clinical Pharmacokinetics of Mefloquine , 1990, Clinical pharmacokinetics.

[19]  N. White.  The parasite clearance curve , 2011, Malaria Journal.

[20]  R. Price,et al.  Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. , 1995, Bulletin of the World Health Organization.

[21]  M. MacDonald,et al.  High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand. , 1993, Bulletin of the World Health Organization.

[22]  R. Steketee,et al.  Mefloquine therapy for Plasmodium falciparum malaria in children under 5 years of age in Malawi: in vivo/in vitro efficacy and correlation of drug concentration with parasitological outcome. , 1990, Bulletin of the World Health Organization.